Tradestie Institutional Equity Comparison Engine
BAX vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BAX Overall Edge
BAX Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Baxter International Inc. (BAX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BAX trades at 12.5x Forward P/E with 7.6% operating margin (+5.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, BAX sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
BAX
BAX 12.5x vs LYRA N/M Fwd P/E
Growth & Margin Winner
BAX
Op Margin 7.6% vs -25032.0% ยท YoY +5.0% vs -87.2%
Momentum & Technical Winner
BAX
1Y +39.9% vs -94.3% ยท 52W Pos 71% vs 1%
Options & Structure Winner
BAX
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
BAX
NYSE
Baxter International Inc.
Surgical & Medical Instruments & Apparatus
$25.83
+1.14% 1D
Market Cap
$13.4B
1M Return
+3.36%
1Y Return
+39.85%
Forward P/E
12.5x
Unified AI Score
46.5 / 100
HOLD
Tech 47.0
Fund 56.0
Flow 71.0
Mom 50.0
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BAX +39.85%
LYRA -94.34%
Spread: +79.61 pp (BAX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BAX Revenue | LYRA Revenue | BAX Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $11.1B | N/A | 14.3% | N/A | BAX |
| FY2019 | $11.4B | N/A | 15.6% | N/A | BAX |
| FY2020 | $11.7B | N/A | 13.8% | N/A | BAX |
| FY2021 | $12.2B | $0M | 11.1% | -15303.5% | BAX |
| FY2022 | $10.1B | $0M | -28.3% | -4131.0% | BAX |
| FY2023 | $10.4B | $0M | 6.8% | -4308.1% | BAX |
| FY2024 | $10.6B | $0M | 0.1% | -6280.8% | BAX |
| FY2025 | $11.2B | $0M | -2.7% | -7794.5% | BAX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BAX | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $13.4B | $2.3M | Larger Scale | BAX |
| Trailing P/E Ratio Valuation | 12.2x | N/M | Lower Multiple | BAX |
| Forward P/E Ratio Valuation | 12.5x | N/M | Lower Multiple | BAX |
| Revenue Growth (YoY) Growth | +5.0% | -87.2% | Higher Growth | BAX |
| Operating Margin (TTM) Profitability | 7.6% | -25032.0% | Higher Margin | BAX |
| Net Profit Margin Profitability | -6.2% | 0.0% | Higher Margin | LYRA |
| Return on Equity (ROE) Capital Efficiency | -9.0% | -404.5% | Higher ROE | BAX |
| 52-Week Range Position Momentum | 71% ($16โ$30) | 1% ($0โ$38) | Stronger Trend | BAX |
| Beta / 30D Volatility Risk Regime | 0.95ฮฒ ยท 47% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | BAX |
| Unified Institutional Score Composite Signal | 46.5 / 100 (HOLD) | 52.2 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BAX vs LYRA Buy Guide
BAX
CONSOLIDATION
74d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BAX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.